EMEA-001760-PIP01-15-M03

Key facts

Invented name
Lartruvo
Active substance
Olaratumab
Therapeutic area
Oncology
Decision number
P/0112/2019
PIP number
EMEA-001760-PIP01-15-M03
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of osteosarcoma
  • Treatment of soft tissue sarcoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Eli Lilly and Company Limited

Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating